Literature DB >> 33251568

Short-Course Systemic and Topical Non-Steroidal Anti-Inflammatory Drugs: Impact on Adverse Renal Events in Older Adults with Co-Morbid Disease.

Cynthia Ciwei Lim1, Andrew Teck Wee Ang2, Hanis Bte Abdul Kadir3, Puay Hoon Lee4,5, Bandy Qiuling Goh2, Sudha Harikrishnan5, Jia Liang Kwek6, Sheryl S W Gan6, Jason Chon Jun Choo6, Ngiap Chuan Tan2.   

Abstract

BACKGROUND: Prolonged systemic non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with adverse renal outcomes among older adults. However, there is scant data regarding the renal safety of topical and short-course systemic NSAIDs. We aimed to evaluate the risk of acute adverse renal outcomes among older adults prescribed topical and short-term systemic NSAIDs.
METHODS: We conducted a retrospective cohort study of all older adults, age 60 years and above, who received prescriptions between July 2015 and December 2017 from the largest tertiary hospital and a major public primary care institution in Singapore. Data from 6 months before until 30 days after the first prescription were retrieved from electronic medical records. The primary outcome was the incidence of acute kidney injury (serum creatinine increased >26.5 µmol/L or >50% from baseline) and/or hyperkalemia within 30 days. A multi-variate analysis taking into account age, sex, co-morbidities, baseline-estimated glomerular filtration rate and serum potassium, NSAID route of administration, and concurrent renin-angiotensin-aldosterone system blocker and diuretic prescription was performed to evaluate factors associated with the primary outcome.
RESULTS: We identified 12,773 older adults with incident prescriptions: 3982 (31.2%) received short-course systemic NSAIDs, 3784 (29.6%) received topical NSAIDs, and 5007 (39.2%) did not receive any NSAID. Both short-course systemic NSAIDs (adjusted odds ratio [OR] 1.59, 95% confidence interval [CI] 1.41-1.80, p < 0.001) and topical NSAIDs (adjusted OR 1.48, 95% CI 1.31-1.67, p < 0.001), compared with the no-NSAID group, were independently associated with the primary outcome. Among older adults with co-morbid conditions and prescribed NSAIDs, topical NSAIDs had a reduced odds of 30-day incident acute kidney injury and/or hyperkalemia in diabetes mellitus (adjusted OR 0.78, 95% CI 0.65-1.06, p = 0.007), chronic kidney disease (adjusted OR 0.74, 95% CI 0.60-0.90, p = 0.003), and cardiovascular disease (adjusted OR 0.54, 95% CI 0.37-0.79, p < 0.001), compared with short-course systemic NSAIDs.
CONCLUSIONS: NSAIDs increased the risk of acute adverse renal events. Topical NSAIDs, compared with short-course systemic NSAIDs, were associated with a reduced incidence of acute kidney injury and/or hyperkalemia among older adults with additional risk factors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33251568     DOI: 10.1007/s40266-020-00824-4

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  1 in total

1.  Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure.

Authors:  J M Evans; E McGregor; A D McMahon; M M McGilchrist; M C Jones; G White; D G McDevitt; T M MacDonald
Journal:  QJM       Date:  1995-08
  1 in total
  3 in total

Review 1.  Pharmacological management of chronic non-cancer pain in frail older people.

Authors:  Gloria Wong
Journal:  Aust Prescr       Date:  2022-02-01

2.  Characterising risk of non-steroidal anti-inflammatory drug-related acute kidney injury: a retrospective cohort study.

Authors:  Sharon X Lin; Thomas Phillips; David Culliford; Christopher Edwards; Christopher Holroyd; Kinda Ibrahim; Ravina Barrett; Clare Howard; Ruth Johnson; Jo Adams; Mathew Stammers; Adam Rischin; Paul Rutter; Nicola Barnes; Paul J Roderick; Simon Ds Fraser
Journal:  BJGP Open       Date:  2022-03-22

Review 3.  From Pathogenesis to Therapy in Knee Osteoarthritis: Bench-to-Bedside.

Authors:  Elena Rezuş; Alexandra Burlui; Anca Cardoneanu; Luana Andreea Macovei; Bogdan Ionel Tamba; Ciprian Rezuş
Journal:  Int J Mol Sci       Date:  2021-03-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.